Company Profile
Sareum Holdings plc, a clinical stage small molecule drug development company provides the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications
SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors completion of initial stage expected Q4 2025.
Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. Incorporated in 2004, the company is headquartered in Cambridge, the United Kingdom.